Abstract:Background: Vascular invasion is a major risk factor for poor prognosis of liver transplantation (LT) for hepatocellular carcinoma (HCC), and this study aimed to evaluate the feasibility and efficacy of deceased donor LT (DDLT) for the treatment of microvascular invasion (MVI) and segmental portal vein tumor thrombus (PVTT). Methods: We retrospectively analyzed 141 patients who received DDLT for HCC combined with vascular invasion from January 2016 to December 2023 at Shulan (Hangzhou) Hospital. To assess the risk of vascular invasion associated with the LT prognosis, we evaluated various clinicopathologic variables. The recurrence-free survival (RFS) and overall survival (OS) based on different types of vascular invasion were also analyzed. Results: A total of 141 patients were enrolled in this study, including patients with MVI (MVI group, n=60), segmental PVTT with segmental branches of the portal vein or above (segmental PVTT group, n=13), and lobar PVTT involving the left and right branches of the portal vein or the main portal vein (lobar PVTT group, n=68). Between the tumor recurrence group and the no recurrence group, there were significant differences in alpha-fetoprotein (AFP) level, tumor total diameter, pretransplant treatment, histological grade, and types of vascular invasion. Subgroup analyses were performed according to the types of vascular invasion, the lobar PVTT group had a significantly higher recurrence rate (lobar vs. MVI: 88.2% vs. 35.0%, lobar vs. segmental: 88.2% vs. 30.8%, both P<0.001), but there was no difference in recurrence rate between the MVI group and the segmental PVTT group (35.0% vs. 30.8%, P>0.99). The 3-year RFS rate and OS rate were as low as 9.1% and 45.9% in the lobar PVTT group, compared with 65.5% and 76.0% in the MVI group, 58.3% and 75.0% in the segmental PVTT group. Multivariate analysis showed that Child-Pugh classification, tumor total diameter, histological grade, and lobar PVTT were the main risk factors affecting RFS, whereas Child-Pugh classification, tumor total diameter, and lobar PVTT were the main risk factors affecting OS. Finally, analysis of the segmental PVTT group revealed that RFS was significantly higher in well and moderately-differentiated patients than in poor-differentiated patients (P=0.01). Conclusions: Lobar PVTT remains a contraindication to LT, whereas segmental PVTT can still be considered for LT after careful screening.

Reply to ‘how to Select Eligible Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus for Deceased Donor Liver Transplantation?’

Liver transplantation for advanced hepatocellular carcinoma: Controversy over portal vein tumor thrombosis

Treatment Options for Portal Hypertension in the Era of Liver Transplantation

Clinical Analysis of hepatocellular carcinoma patients with segmental portal vein tumor thrombus after deceased donor liver transplantation: a long-term retrospective study

Long-term Outcomes of Deceased Donor Liver Transplantation in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Multicenter Study.

Clinical analysis of deceased donor liver transplantation in the treatment of hepatocellular carcinoma with segmental portal vein tumor thrombus: A long-term real-world study

Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II

Alpha-fetoprotein and 18F-FDG Standard Uptake Value Predict Tumor Recurrence after Liver Transplantation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Preliminary Experience.

The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy

Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future

A Single‐center Retrospective Analysis of Liver Transplantation on 255 Patients with Hepatocellular Carcinoma

Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides

Liver Transplant Recipients with Portal Vein Thrombosis:A Single Center Retrospective Study

Surgical Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

[Liver Transplantation for the Patients with End Stage Liver Disease and Portal Vein Thrombosis].

Response to Pretransplant Downstaging Therapy Predicts Patient Outcome after Liver Transplantation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Orthotopic liver transplantation for patients with hepatocellular carcinoma complicated by portal vein tumor thrombi.

[Liver Transplantation for Hepatocellular Carcinoma: Prognostic Analysis of 89 Cases].

The clinical outcomes of patients with vascular invasion after deceased donor liver transplantation

Surgical Strategy For Hepatocellular Carcinoma Patients With Portal/Hepatic Vein Tumor Thrombosis